GlassScriptPhysician profile
David A Goldman
NPI 1871538116
$238,694.77
in general payments reported to CMS, 2019-2025
40 companies · $19K in 2025
The $19K reported for 2025 was more than what 97% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $44K · 2020: $54K · 2021: $37K · 2022: $31K · 2023: $25K · 2024: $29K · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $47K · Consulting Fee: $13K · Food and Beverage: $9,410 · Honoraria: $2,750 · Travel and Lodging: $741 · Education: $87.70 · Long Term Medical Supply Or Device Loan: $16.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $46,690.00 |
| Consulting Fee | $13,475.00 |
| Food and Beverage | $9,410.31 |
| Honoraria | $2,750.00 |
| Travel and Lodging | $741.47 |
| Education | $87.70 |
| Long Term Medical Supply Or Device Loan | $16.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $79,283.61 | 2019-2022 | |
| Rayner Intraocular Lenses Limited | $60,919.96 | 2022-2025 | Rayone Spheric, Rayone Aspheric, Rayone Emv |
| Alcon Vision LLC | $14,279.86 | 2019-2025 | Clareon, Hydrus Microstent, Clareon Panoptix Pro |
| Carl Zeiss Meditec, INC. | $11,337.69 | 2019-2024 | Veracity Surgical |
| Abbvie INC. | $10,602.61 | 2021-2025 | |
| Sight Sciences, INC. | $10,353.33 | 2019-2025 | Omni Surgical System, Tearcare System |
| Ocular Therapeutix, INC. | $9,319.50 | 2019-2024 | Dextenza |
| Shire North American Group INC | $7,211.26 | 2019 | |
| Sun Pharmaceutical Industries INC. | $5,542.47 | 2019-2025 | Cequa |
| Eyevance Pharmaceuticals LLC | $5,377.24 | 2019-2023 | Flarex |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $5,288.17 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $3,638.13 | 2019-2023 | |
| Optos, INC. | $3,500.00 | 2020-2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope |
| Tearlab Corp | $1,749.81 | 2021-2024 | Tearlab Osmolarity System, Scoutpro Osmolarity System |
| Johnson & Johnson Surgical Vision, INC. | $1,281.82 | 2019-2025 | Tecnis Simplicity, Tecnis Iol |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Topcon Healthcare, INC. | $1,264.31 | 2025 | |
| Bausch & Lomb Americas INC. | $1,161.72 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Glaukos Corporation | $1,073.31 | 2019-2025 | Idose, Photrexa Viscous and Photrexa, Ce-Marked Kxla System |
| Mallinckrodt Hospital Products INC. | $989.00 | 2021-2025 | Acthar |
| Dompe US, INC. | $729.10 | 2019-2025 | Oxervate |
| Kala Pharmaceuticals, INC. | $519.01 | 2019-2022 | |
| Nordic Pharma, INC. | $480.15 | 2025 | Lacrifill |
| Oyster Point Pharma, INC. | $385.53 | 2022-2025 | Tyrvaya, Ryzumvi |
| New World Medical,INC. | $378.18 | 2022-2025 | Clearpath, Streamline, Kahook Dual Blade |
| Tarsus Pharmaceuticals, INC. | $317.88 | 2024-2025 | Xdemvy |
| Lensar, INC. | $262.81 | 2024-2025 | Lensar Laser System |
| Harrow Eye, LLC | $237.11 | 2024-2025 | Vevye, Triesence, Iheezo |
| Ani Pharmaceuticals, INC. | $216.77 | 2024-2025 | Purified Cortrophin Gel |
| Biotissue Holdings INC. | $202.39 | 2019-2023 | |
| Dutch Ophthalmic, USA | $168.41 | 2024 | Eva, Combined Machine, Tissueblue |
| Aerie Pharmaceuticals, INC. | $136.90 | 2019-2021 | |
| Genentech USA, INC. | $97.69 | 2024 | Vabysmo |
| Omeros Corporation | $84.46 | 2019-2021 | |
| Eyepoint US, INC. | $74.37 | 2019 | |
| Amgen INC. | $64.26 | 2024-2025 | Tepezza |
| Rxsight INC | $60.05 | 2023-2024 | Rxsight Contact Lens, Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Horizon Therapeutics Plc | $36.36 | 2022-2023 | Tepezza |
| Ivantis, INC | $30.99 | 2019 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Apellis Pharmaceuticals, INC. | $19.15 | 2025 | Syfovre |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$300,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Goldman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.